Meant Health, a digital health platform that connects patients with licensed clinicians for evaluation, prescription and ongoing care coaching, announced on Saturday that it is expanding telehealth access to FDA-approved GLP-1 medications.
The aim is to shorten the distance between someone wondering whether a treatment might be right for them, and an actual conversation with a US-licensed clinician who could review their history and make that call.
As more people look for a straightforward way to access Ozempic, Meant Health says it is expanding its telehealth platform to connect patients with licensed clinicians for evaluation and prescription. It starts with an intake questionnaire that walks through health history, current medications and what the patient is hoping to address. A licensed clinician then reviews that information and decides, case by case, whether a prescription makes sense.
Ozempic is FDA-approved for the treatment of type 2 diabetes; when it's prescribed for weight management, that use is off-label and remains entirely at the clinician's discretion. Patients who do receive a prescription are paired with ongoing care coaching, providing a steady point of contact as their plan unfolds rather than a one-time appointment.
AstraZeneca's Etcamah misses primary endpoint in Phase III breast cancer trial
GSK reports positive Jideytro data supporting potential first-line lung cancer use
Meant Health announces expansion of telehealth access for FDA-approved GLP-1 prescriptions
Akeso presents positive results from registrational Phase III study of ivonescimab
US FDA grants orphan drug designation for Lundbeck's asedebart
ABL Diagnostics files bid to acquire IntegraGen
ABEC opens new manufacturing facility in Wilson, NC
Seismic Pharmaceuticals enrols first patient in istaroxime global Phase 3 trial in cardiogenic shock
Insilico Medicine doses first patient in Phase III trial of rentosertib
Tyra Biosciences declares positive Phase 2 results for oral dabogratinib in bladder cancer
Harbour BioMed partner raises USD225m to advance neoadjuvant immuno-oncology therapy porustobart
Kazia Therapeutics doses first patient in paediatric AT/RT study
Revvity to acquire Human Cell Design to expand metabolic disease drug discovery capabilities
Altesa BioSciences presents positive vapendavir clinical data at ERS International Congress 2026